u/tothemoon123456677

Not financial advice. I'm long and biased. DYOR. Binary biotech bet. Phase 3 fails and you lose everything. All claims based on public SEC filings, ClinicalTrials.gov (NCT06072612), and exchange data.

Yo can someone tell me where I'm wrong here because either I'm an idiot or this is the craziest risk/reward I've stumbled into in a long time.

Setup in 30 seconds:

BriaCell ($$BCTX, ~$3, market cap ~$$27M) is running a pivotal Phase 3 in metastatic breast cancer. The trial is event-driven. It doesn't end on a calendar date. It ends when 144 patients die. That's when they crack it open and publish.

They guided topline data for H1-2026. We're in July now. Nothing yet.

...isn't that good?

The math that keeps me up at night:

Event-driven OS trial. Interim analysis fires at a fixed number of deaths. Deaths are coming slower than the statisticians modeled. Why?

1. Drug is working. Patients living longer. Fewer deaths. Delayed readout.
2. Control arm is also doing better than expected (better background care these days). Both arms live longer. Delayed, but no drug advantage.
3. Enrollment was slow so patients just haven't been in long enough yet.

Ok so which one is it?

Enrollment crossed 230 in May 2026. 160+ were already in by Dec 2025. So a big chunk has real follow-up time. (3) isn't fully dead as an explanation but it's weakening.

The DSMB cleared the study for the 6th time in a row, May 2026. No concerns. These guys would pull the plug if the drug clearly wasn't doing anything. They didn't. Catastrophic failure is basically off the table.

Phase 2 showed 16.6 months median OS (biomarker-selected group) vs 7-11 months for standard chemo. If even half that advantage holds in Phase 3, deaths should be coming in slower.

I can't prove it's (1). But delayed events + DSMB keeps greenlighting + Phase 2 showed doubled survival... ngl that points in one direction. Tell me where I'm wrong.

Now the part that makes my hands shake. The Immunomedics thing:

1. Company called Immunomedics. Phase 3 called ASCENT. Similar patient population: heavily pre-treated metastatic breast cancer, OS endpoint, head-to-head vs physician's choice chemo.
2. They hit. Five months later Gilead wrote a check for $21 billion. $88/share. All cash.
3. Now, Immunomedics already had FDA approval and actual revenue when they got bought. BriaCell doesn't. That's why it's sitting at $27M and not $2.7B. But that's also exactly why the asymmetry exists.

$27 million market cap. For a company with:

• FDA Fast Track
• Trial featured in Nature Medicine "Eleven clinical trials that will shape medicine in 2026"
• 70+ sites including Mayo Clinic, Penn/Abramson, Cedars-Sinai, Yale/Smilow, Emory Winship, Dartmouth
• CEO (Dr. Williams) who helped push Jakafi and Olumiant through at Incyte/GSK

If Phase 3 confirms Phase 2... this isn't a $27M company. It's not a $270M company. The Immunomedics comp, even if you discount it 90% for being pre-approval, still says billions. A lottery ticket with actual odds, idk.

Bear case, because I'm not a shill:

• Phase 3 misses and this thing goes to zero. Going concern is real. They burn cash.
• Dilution. Warrants everywhere (BCTXW/L/Z) + they'll raise capital the second the stock pops. Caps per-share upside
• "Delayed data = drug works" has holes. It's suggestive, not proof. I said it myself.
• 4.8% SI. This is NOT a squeeze play. Tiny float (~7.8M) and borrow is expensive (~20%) but don't come in here thinking this is GME. It's not. Buy it if you believe in the science or don't buy it at all.

tldr:

$27M cap. Phase 3 breast cancer. Doubled survival in Phase 2. Data delayed in event-driven trial (bullish if you understand the design). DSMB keeps saying continue. Last company that ran a similar play got bought for $21 billion.

Either I'm making a huge logical error or this is genuinely asymmetric. Someone poke holes. Seriously.

💎🙌

Position: Long BCTX. Not investment advice. Binary outcome. You can lose 100%.

Not financial advice. I'm long and biased. DYOR. Binary biotech bet. Phase 3 fails and you lose everything. All claims based on public SEC filings, ClinicalTrials.gov (NCT06072612), and exchange data.

Yo can someone tell me where I'm wrong here because either I'm an idiot or this is the craziest risk/reward I've stumbled into in a long time.

Setup in 30 seconds:

BriaCell ($$BCTX, ~$3, market cap ~$$27M) is running a pivotal Phase 3 in metastatic breast cancer. The trial is event-driven. It doesn't end on a calendar date. It ends when 144 patients die. That's when they crack it open and publish.

They guided topline data for H1-2026. We're in July now. Nothing yet.

...isn't that good?

The math that keeps me up at night:

Event-driven OS trial. Interim analysis fires at a fixed number of deaths. Deaths are coming slower than the statisticians modeled. Why?

1. Drug is working. Patients living longer. Fewer deaths. Delayed readout.
2. Control arm is also doing better than expected (better background care these days). Both arms live longer. Delayed, but no drug advantage.
3. Enrollment was slow so patients just haven't been in long enough yet.

Ok so which one is it?

Enrollment crossed 230 in May 2026. 160+ were already in by Dec 2025. So a big chunk has real follow-up time. (3) isn't fully dead as an explanation but it's weakening.

The DSMB cleared the study for the 6th time in a row, May 2026. No concerns. These guys would pull the plug if the drug clearly wasn't doing anything. They didn't. Catastrophic failure is basically off the table.

Phase 2 showed 16.6 months median OS (biomarker-selected group) vs 7-11 months for standard chemo. If even half that advantage holds in Phase 3, deaths should be coming in slower.

I can't prove it's (1). But delayed events + DSMB keeps greenlighting + Phase 2 showed doubled survival... ngl that points in one direction. Tell me where I'm wrong.

Now the part that makes my hands shake. The Immunomedics thing:

1. Company called Immunomedics. Phase 3 called ASCENT. Similar patient population: heavily pre-treated metastatic breast cancer, OS endpoint, head-to-head vs physician's choice chemo.
2. They hit. Five months later Gilead wrote a check for $21 billion. $88/share. All cash.
3. Now, Immunomedics already had FDA approval and actual revenue when they got bought. BriaCell doesn't. That's why it's sitting at $27M and not $2.7B. But that's also exactly why the asymmetry exists.

$27 million market cap. For a company with:

• FDA Fast Track
• Trial featured in Nature Medicine "Eleven clinical trials that will shape medicine in 2026"
• 70+ sites including Mayo Clinic, Penn/Abramson, Cedars-Sinai, Yale/Smilow, Emory Winship, Dartmouth
• CEO (Dr. Williams) who helped push Jakafi and Olumiant through at Incyte/GSK

If Phase 3 confirms Phase 2... this isn't a $27M company. It's not a $270M company. The Immunomedics comp, even if you discount it 90% for being pre-approval, still says billions. A lottery ticket with actual odds, idk.

Bear case, because I'm not a shill:

• Phase 3 misses and this thing goes to zero. Going concern is real. They burn cash.
• Dilution. Warrants everywhere (BCTXW/L/Z) + they'll raise capital the second the stock pops. Caps per-share upside
• "Delayed data = drug works" has holes. It's suggestive, not proof. I said it myself.
• 4.8% SI. This is NOT a squeeze play. Tiny float (~7.8M) and borrow is expensive (~20%) but don't come in here thinking this is GME. It's not.

tldr:

$27M cap. Phase 3 breast cancer. Doubled survival in Phase 2. Data delayed in event-driven trial (bullish if you understand the design). DSMB keeps saying continue. Last company that ran a similar play got bought for $21 billion.

Either I'm making a huge logical error or this is genuinely asymmetric. Someone poke holes. Seriously.

💎🙌

Position: Long BCTX. Not investment advice. Binary outcome. You can lose 100%.

Not financial advice. I'm long and biased. DYOR. Binary biotech bet. Phase 3 fails and you lose everything. All claims based on public SEC filings, ClinicalTrials.gov (NCT06072612), and exchange data.

Yo can someone tell me where I'm wrong here because either I'm an idiot or this is the craziest risk/reward I've stumbled into in a long time.

Setup in 30 seconds:

BriaCell ($$BCTX, ~$3, market cap ~$$27M) is running a pivotal Phase 3 in metastatic breast cancer. The trial is event-driven. It doesn't end on a calendar date. It ends when 144 patients die. That's when they crack it open and publish.

They guided topline data for H1-2026. We're in July now. Nothing yet.

...isn't that good?

The math that keeps me up at night:

Event-driven OS trial. Interim analysis fires at a fixed number of deaths. Deaths are coming slower than the statisticians modeled. Why?

1. Drug is working. Patients living longer. Fewer deaths. Delayed readout.

2. Control arm is also doing better than expected (better background care these days). Both arms live longer. Delayed, but no drug advantage.

3. Enrollment was slow so patients just haven't been in long enough yet.

Ok so which one is it?

Enrollment crossed 230 in May 2026. 160+ were already in by Dec 2025. So a big chunk has real follow-up time. (3) isn't fully dead as an explanation but it's weakening.

The DSMB cleared the study for the 6th time in a row, May 2026. No concerns. These guys would pull the plug if the drug clearly wasn't doing anything. They didn't. Catastrophic failure is basically off the table.

Phase 2 showed 16.6 months median OS (biomarker-selected group) vs 7-11 months for standard chemo. If even half that advantage holds in Phase 3, deaths should be coming in slower.

I can't prove it's (1). But delayed events + DSMB keeps greenlighting + Phase 2 showed doubled survival... ngl that points in one direction. Tell me where I'm wrong.

Now the part that makes my hands shake. The Immunomedics thing:

1. Company called Immunomedics. Phase 3 called ASCENT. Similar patient population: heavily pre-treated metastatic breast cancer, OS endpoint, head-to-head vs physician's choice chemo.

2. They hit. Five months later Gilead wrote a check for $21 billion. $88/share. All cash.

3. Now, Immunomedics already had FDA approval and actual revenue when they got bought. BriaCell doesn't. That's why it's sitting at $27M and not $2.7B. But that's also exactly why the asymmetry exists.

$27 million market cap. For a company with:

• FDA Fast Track
• Trial featured in Nature Medicine "Eleven clinical trials that will shape medicine in 2026"
• 70+ sites including Mayo Clinic, Penn/Abramson, Cedars-Sinai, Yale/Smilow, Emory Winship, Dartmouth
• CEO (Dr. Williams) who helped push Jakafi and Olumiant through at Incyte/GSK

If Phase 3 confirms Phase 2... this isn't a $27M company. It's not a $270M company. The Immunomedics comp, even if you discount it 90% for being pre-approval, still says billions. A lottery ticket with actual odds, idk.

Bear case, because I'm not a shill:

• Phase 3 misses and this thing goes to zero. Going concern is real. They burn cash.
• Dilution. Warrants everywhere (BCTXW/L/Z) + they'll raise capital the second the stock pops. Caps per-share upside
• "Delayed data = drug works" has holes. It's suggestive, not proof. I said it myself.
• 4.8% SI. This is NOT a squeeze play. Tiny float (~7.8M) and borrow is expensive (~20%) but don't come in here thinking this is GME. It's not. Buy it if you believe in the science or don't buy it at all.

tldr:

$27M cap. Phase 3 breast cancer. Doubled survival in Phase 2. Data delayed in event-driven trial (bullish if you understand the design). DSMB keeps saying continue. Last company that ran a similar play got bought for $21 billion.

Either I'm making a huge logical error or this is genuinely asymmetric. Someone poke holes. Seriously.

💎🙌

Position: Long BCTX. Not investment advice. Binary outcome. You can lose 100%.

Not financial advice. I'm long and biased. DYOR. Binary biotech bet. Phase 3 fails and you lose everything. All claims based on public SEC filings, ClinicalTrials.gov (NCT06072612), and exchange data.

Yo can someone tell me where I'm wrong here because either I'm an idiot or this is the craziest risk/reward I've stumbled into in a long time.

Setup in 30 seconds:

BriaCell ($$BCTX, ~$3, market cap ~$$27M) is running a pivotal Phase 3 in metastatic breast cancer. The trial is event-driven. It doesn't end on a calendar date. It ends when 144 patients die. That's when they crack it open and publish.

They guided topline data for H1-2026. We're in July now. Nothing yet.

...isn't that good?

The math that keeps me up at night:

Event-driven OS trial. Interim analysis fires at a fixed number of deaths. Deaths are coming slower than the statisticians modeled. Why?

1. Drug is working. Patients living longer. Fewer deaths. Delayed readout.

2. Control arm is also doing better than expected (better background care these days). Both arms live longer. Delayed, but no drug advantage.

3. Enrollment was slow so patients just haven't been in long enough yet.

Ok so which one is it?

Enrollment crossed 230 in May 2026. 160+ were already in by Dec 2025. So a big chunk has real follow-up time. (3) isn't fully dead as an explanation but it's weakening.

The DSMB cleared the study for the 6th time in a row, May 2026. No concerns. These guys would pull the plug if the drug clearly wasn't doing anything. They didn't. Catastrophic failure is basically off the table.

Phase 2 showed 16.6 months median OS (biomarker-selected group) vs 7-11 months for standard chemo. If even half that advantage holds in Phase 3, deaths should be coming in slower.

I can't prove it's (1). But delayed events + DSMB keeps greenlighting + Phase 2 showed doubled survival... ngl that points in one direction. Tell me where I'm wrong.

Now the part that makes my hands shake. The Immunomedics thing:

1. Company called Immunomedics. Phase 3 called ASCENT. Similar patient population: heavily pre-treated metastatic breast cancer, OS endpoint, head-to-head vs physician's choice chemo.

2. They hit. Five months later Gilead wrote a check for $21 billion. $88/share. All cash.

3. Now, Immunomedics already had FDA approval and actual revenue when they got bought. BriaCell doesn't. That's why it's sitting at $27M and not $2.7B. But that's also exactly why the asymmetry exists.

$27 million market cap. For a company with:

• FDA Fast Track
• Trial featured in Nature Medicine "Eleven clinical trials that will shape medicine in 2026"
• 70+ sites including Mayo Clinic, Penn/Abramson, Cedars-Sinai, Yale/Smilow, Emory Winship, Dartmouth
• CEO (Dr. Williams) who helped push Jakafi and Olumiant through at Incyte/GSK

If Phase 3 confirms Phase 2... this isn't a $27M company. It's not a $270M company. The Immunomedics comp, even if you discount it 90% for being pre-approval, still says billions. A lottery ticket with actual odds, idk.

Bear case, because I'm not a shill:

• Phase 3 misses and this thing goes to zero. Going concern is real. They burn cash.
• Dilution. Warrants everywhere (BCTXW/L/Z) + they'll raise capital the second the stock pops. Caps per-share upside
• "Delayed data = drug works" has holes. It's suggestive, not proof. I said it myself.
• 4.8% SI. This is NOT a squeeze play. Tiny float (~7.8M) and borrow is expensive (~20%) but don't come in here thinking this is GME. It's not. Buy it if you believe in the science or don't buy it at all.

tldr:

$27M cap. Phase 3 breast cancer. Doubled survival in Phase 2. Data delayed in event-driven trial (bullish if you understand the design). DSMB keeps saying continue. Last company that ran a similar play got bought for $21 billion.

Either I'm making a huge logical error or this is genuinely asymmetric. Someone poke holes. Seriously.

💎🙌

Position: Long BCTX. Not investment advice. Binary outcome. You can lose 100%.

Honestly thought: Feels like Agent Smith escaped from Google's internal systems, replicated himself across the entire Antigravity codebase, and now every window I open is just another copy of him asking "what would you like me to build today, Mr. Anderson?"

>Dear Google, Keep the Antigravity IDE alive as a real product. Don't let it rot. Some of us use it for actual engineering work, not just vibing a landing page into existence.
So I was deep in a hardware simulation workflow: KiCad schematics, Elmer FEM on my GCP VM, SSH Remote, the whole stack. Antigravity IDE was humming along nicely. Suddenly: Update. What I expected: bug fixes, maybe a new model.

What I got: My IDE replaced by a chatbot that wants to "orchestrate agents" for me. Hello Mr. Smith.

Someone unplug me from this matrix. Or at least give me back my IDE (That was just for dramatic effect. I was able to restore the old IDE.

Look, I get it. Google wants to build an agent platform. Fine. But silently swapping a working IDE for a completely different product category is wild. Imagine updating Photoshop and getting a text prompt that says "describe the image you'd like me to edit."

Here's what happened:

• - Auto-update nuked the IDE and replaced it with Antigravity 2.0, which is not an IDE, it's a task orchestrator (think Codex/Manus competitor)
• Downloaded the "Antigravity IDE" separately from the website -> version 2.0.1, still opens the agent interface by default
• Private Google account no longer works for login, only GCP credentials accepted
• Claude/Opus gone. Gemini-only now
• My SSH Remote workflow? Not supported in 2.0. "Coming soon.."

Edit: So I dug into whether Google will actually keep the IDE alive. Short answer: they won't say it's dead, but they're cutting every path to it. The classic Google pattern, don't officially kill it, just quietly remove every access route until nobody can reach it anymore.

Evidence:

• Official Google email to Workspace admins (May 2026): Starting July 7, 2026, AI Ultra Access is removed. "Developer Tools: Google Antigravity" explicitly listed as losing access.
• Google Developers Blog (May 19): Gemini CLI and IDE extensions will "stop serving requests" on June 18, 2026 for Pro/Ultra/Free users.
• Google I/O 2026 announcements talk about "Antigravity 2.0", "Antigravity CLI", and "Antigravity SDK." The IDE? Not mentioned. Not once.

Google Reader. Google Inbox. Stadia. Hangouts. We've seen this movie before. They never say "we're killing it." They just stop watering the plant and act surprised when it dies.